Comparison of the efficacy of accelerated corneal cross-linking therapy in different pediatric age groups having progressive keratoconus.

Ozer M. D., Batur M., Mesen S., Tekın S., Seven E., Yasar T.

International ophthalmology, cilt.40, ss.2651-2658, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1007/s10792-020-01446-w
  • Dergi Adı: International ophthalmology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2651-2658
  • Anahtar Kelimeler: Keratoconus, Accelerated corneal cross-linking, Orbscan, Keratometry, Pediatric age, RISK-FACTORS, OUTCOMES
  • Van Yüzüncü Yıl Üniversitesi Adresli: Evet

Özet

Purpose To report a comparison analysis of accelerated corneal cross-linking (A-CXL) treatment for progressive keratoconus patients in different pediatric age groups. Study design Retrospective, cross-sectional. Methods Patients with progressive keratoconus aged <= 18 were retrospectively reviewed. Forty-one eyes of 41 patients were included in the study. Patients were divided into two groups according to their age (<= 14 years and 15-18 years). All patients underwent epithelium-off A-CXL protocol. Acquired data were compared between the two groups. Results The mean age was 14.3 +/- 1.8 (10-18) years. Twenty-five (61%) of the participants were male, and 16 (39%) were female. Twenty (49%) patients were separated into group 1 (<= 14 years of age), and 21 (51%) were in group 2 (15-18 years). Age at presentation was found to be the only factor in anticipating the progression of keratoconus at the second postoperative year visit (p < 0.001). Progression in keratometric values was detected in seven (35%) of the 20 eyes in group 1, and one (4%) of the 21 patients in group 2 (Z = - 2.44, p = 0.014). Conclusion Even if proper treatment is applied, the progression of keratoconus is likely in patients younger than 14 years of age. Instead of evaluating pediatric patients as a whole, closer follow-up and early treatment may be useful in younger age groups (<= 14 years).